Dianthus Therapeutics, Inc./$DNTH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
Ticker
$DNTH
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
78
ISIN
US2528281080
Website
DNTH Metrics
BasicAdvanced
$567M
-
-$2.81
-
-
Price and volume
Market cap
$567M
52-week high
$24.81
52-week low
$13.37
Average daily volume
287K
Financial strength
Current ratio
15.985
Quick ratio
15.586
Long term debt to equity
0.356
Total debt to equity
0.425
Profitability
EBITDA (TTM)
-117.096
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-1,544.02%
Operating margin (TTM)
-1,796.40%
Revenue per employee (TTM)
$80,000
Management effectiveness
Return on assets (TTM)
-20.04%
Return on equity (TTM)
-28.73%
Valuation
Price to revenue (TTM)
96.865
Price to book
1.72
Price to tangible book (TTM)
1.72
Price to free cash flow (TTM)
-6.947
Free cash flow yield (TTM)
-14.39%
Free cash flow per share (TTM)
-253.77%
Growth
Revenue change (TTM)
102.36%
Earnings per share change (TTM)
-36.47%
Bulls say / Bears say
TD Cowen initiated coverage of Dianthus Therapeutics with a 'Buy' recommendation, indicating strong confidence in the company's future prospects. (nasdaq.com)
Analysts have set an average 12-month price target of $54.33 for DNTH, suggesting significant potential upside from its current trading price. (americanbankingnews.com)
Dianthus Therapeutics has completed enrollment for its Phase 2 MaGic trial of DNTH103 in generalized myasthenia gravis, with top-line results expected in September, which could serve as a positive catalyst for the stock. (stocktitan.net)
Dianthus Therapeutics reported a Q4 loss of $0.81 per share, missing revenue estimates, which may raise concerns about the company's financial performance. (nasdaq.com)
The company has a negative net profit margin of -1,362.77%, indicating significant financial challenges that could impact investor confidence. (stocktitan.net)
Short interest in Dianthus Therapeutics increased significantly, with 6,000,000 shares sold short as of January 15th, suggesting that some investors are betting against the stock. (defenseworld.net)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.
DNTH News
AllArticlesVideos
Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference
GlobeNewsWire·1 month ago
Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors
GlobeNewsWire·1 month ago
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Dianthus Therapeutics, Inc. stock?
Dianthus Therapeutics, Inc. (DNTH) has a market cap of $567M as of June 30, 2025.
What is the P/E ratio for Dianthus Therapeutics, Inc. stock?
The price to earnings (P/E) ratio for Dianthus Therapeutics, Inc. (DNTH) stock is 0 as of June 30, 2025.
Does Dianthus Therapeutics, Inc. stock pay dividends?
No, Dianthus Therapeutics, Inc. (DNTH) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Dianthus Therapeutics, Inc. dividend payment date?
Dianthus Therapeutics, Inc. (DNTH) stock does not pay dividends to its shareholders.
What is the beta indicator for Dianthus Therapeutics, Inc.?
Dianthus Therapeutics, Inc. (DNTH) does not currently have a Beta indicator.